<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062927" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq">Chronic Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000039347">chronic myeloproliferative neoplasms</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Chronic Myeloproliferative Neoplasms Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Myeloproliferative Neoplasms Treatment</AltTitle><AltTitle TitleType="Short">Chronic Myeloproliferative Neoplasms Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000039347">chronic myeloproliferative neoplasms</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Chronic Myeloproliferative Neoplasms (MPN)</Title><Para id="_2">The chronic MPN consist of chronic myelogenous leukemia, polycythemia vera (p. vera), primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. All of these disorders involve dysregulation at the multipotent hematopoietic stem cell (CD34), with one or more of the following shared features:</Para><ItemizedList id="_133" Style="bullet"><ListItem>Overproduction of one or several blood elements with dominance of a transformed clone.</ListItem><ListItem>Hypercellular marrow/marrow fibrosis.</ListItem><ListItem>Cytogenetic abnormalities.</ListItem><ListItem>Thrombotic and/or hemorrhagic diatheses.</ListItem><ListItem>Extramedullary hematopoiesis (liver/spleen).</ListItem><ListItem>Transformation to acute leukemia.</ListItem><ListItem>Overlapping clinical features.</ListItem></ItemizedList><Para id="_65">Chronic  MPNs usually occur sporadically; however, familial clusters of MPNs have been reported.  These familial clusters include autosomal-dominant inheritance and  autosomal-recessive inheritance.<Reference refidx="1"/> Patients with p. vera and essential thrombocythemia have marked increases of red blood cell and platelet production, respectively. Treatment is directed at reducing the excessive numbers of blood cells. Both p. vera and essential thrombocythemia can develop a spent phase late in their courses that resembles primary myelofibrosis with cytopenias and marrow hypoplasia and fibrosis.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>
A specific point mutation in one copy of the <GeneName>Janus kinase 2</GeneName> gene (<GeneName>JAK2</GeneName>), a cytoplasmic tyrosine kinase,  on chromosome 9, which causes increased proliferation and survival of hematopoietic precursors <Emphasis>in vitro</Emphasis>, has been  identified in most  patients with p. vera,  essential thrombocythemia,  and idiopathic myelofibrosis.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/> Researchers are pursuing specific targeting of this aberrant protein.</Para><ReferenceSection><Citation idx="1" PMID="23094849">Ranjan A, Penninga E, Jelsig AM, et al.: Inheritance of the chronic myeloproliferative neoplasms. A systematic review. Clin Genet 83 (2): 99-107, 2013.</Citation><Citation idx="2" PMID="6375757" MedlineID="84232487">Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64 (1): 1-12, 1984.</Citation><Citation idx="3" PMID="10561375" MedlineID="20030104">Barosi G: Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (9): 2954-70, 1999.</Citation><Citation idx="4" PMID="10781623" MedlineID="20228762">Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342 (17): 1255-65, 2000.</Citation><Citation idx="5" PMID="15858187">Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (17): 1779-90, 2005.</Citation><Citation idx="6" PMID="15781101">Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464): 1054-61, 2005 Mar 19-25.</Citation><Citation idx="7" PMID="15793561">James C, Ugo V, Le Couédic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (7037): 1144-8, 2005.</Citation><Citation idx="8" PMID="15837627">Levine RL, Wadleigh M, Cools J, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (4): 387-97, 2005.</Citation><Citation idx="9" PMID="17267906">Scott LM, Tong W, Levine RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (5): 459-68, 2007.</Citation><Citation idx="10" PMID="17151367">Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355 (23): 2452-66, 2006.</Citation></ReferenceSection></SummarySection><SummarySection id="_108"><SectMetaData><SpecificDiagnosis ref="CDR0000037900">chronic myelogenous leukemia</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Chronic Myelogenous Leukemia</Title><Para id="_109">Refer to the PDQ summary on <SummaryRef href="CDR0000062876" url="/types/leukemia/hp/cml-treatment-pdq">Chronic
Myelogenous Leukemia Treatment</SummaryRef> for more information.</Para></SummarySection><SummarySection id="_5"><SectMetaData><SpecificDiagnosis ref="CDR0000039350">polycythemia vera</SpecificDiagnosis></SectMetaData><Title>Polycythemia Vera</Title><SummarySection id="_67"><Title>Disease Overview</Title><Para id="_199">The proposed revised World Health Organization criteria for the diagnosis of polycythemia vera (p. vera) requires two major criteria and one minor criterion or the first major criterion together with two minor criteria.<Reference refidx="1"/></Para><OrderedList id="_200" Style="Arabic"><ListTitle>Major Criteria</ListTitle><ListItem>Hemoglobin of more than 18.5 g/dL in men, 16.5 g/dL in women, or elevated red cell mass  greater than 25% above mean normal predicted value.</ListItem><ListItem>Presence of <GeneName>JAK2</GeneName> 617V greater than F or other functionally similar mutations, such as the  exon 12 mutation of <GeneName>JAK2</GeneName>.</ListItem></OrderedList><OrderedList id="_201" Style="Arabic"><ListTitle>Minor Criteria</ListTitle><ListItem>Bone marrow biopsy showing hypercellularity with prominent erythroid, granulocytic, and megakaryocytic proliferation.</ListItem><ListItem>Serum erythropoietin level below normal range.</ListItem><ListItem>Endogenous erythroid colony formation <Emphasis>in vitro</Emphasis>.</ListItem></OrderedList><Para id="_63">Other confirmatory findings no longer required for diagnosis include:<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> 
</Para><ItemizedList id="_64" Style="bullet"><ListItem>Oxygen saturation with arterial blood gas greater than 92%.</ListItem><ListItem>Splenomegaly.</ListItem><ListItem>Thrombocytosis (&gt;400,000 platelets/mm<Superscript>3</Superscript>).</ListItem><ListItem>Leukocytosis (&gt;12,000/mm<Superscript>3</Superscript>).</ListItem><ListItem>Leukocyte alkaline phosphatase (&gt;100 units in the absence of fever or infection).</ListItem></ItemizedList><Para id="_8">There is no staging system for this disease.
</Para><Para id="_152">Patients have an increased risk of cardiovascular and thrombotic events and transformation to acute myelogenous leukemia or primary myelofibrosis.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> Age older than  65 years, leukocytosis, and a history of vascular events (bleeding or thrombosis) are associated with a poor prognosis.<Reference refidx="5"/><Reference refidx="8"/><Reference refidx="9"/></Para></SummarySection><SummarySection id="_68"><Title>Treatment Overview</Title><Para id="_70">The primary therapy for p. vera includes intermittent, chronic phlebotomy to
maintain the hematocrit below 45%, and this recommendation has been confirmed in a randomized, prospective trial, which demonstrated lower rates of cardiovascular death and major thrombosis using this hematocrit target.<Reference refidx="10"/><Reference refidx="11"/> The target level for women may need to be lower (e.g., hematocrit &lt;40%), but there are no empiric data to confirm this recommendation.<Reference refidx="12"/>   </Para><Para id="_231">Complications of phlebotomy include:</Para><ItemizedList id="_232" Style="bullet"><ListItem>Progressive and sometimes
extreme thrombocytosis and symptomatology related to chronic iron deficiency,
including pica, angular stomatitis, and glossitis.</ListItem><ListItem>Dysphagia that is the result of  esophageal
webs (very rare).</ListItem><ListItem>Possibly muscle weakness.</ListItem></ItemizedList><Para id="_233">(Refer to the PDQ summary on <SummaryRef href="CDR0000062870" url="/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq">Oral Complications of Chemotherapy and Head/Neck Radiation</SummaryRef>  for more information.)</Para><Para id="_210">In addition, progressive
splenomegaly or pruritus not controllable by antihistamines may persist despite
control of the hematocrit by phlebotomy.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062748" url="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq">Pruritus</SummaryRef>  for more information.) If phlebotomy becomes impractical,
hydroxyurea or interferon-alpha can be added
to control the disease.  </Para><Para id="_71">The
Polycythemia Vera Study Group randomly assigned more than 400 patients to phlebotomy
(target hematocrit &lt;45), radioisotope phosphorous-32 (2.7 mg/m<Superscript>2</Superscript> administered  intravenously every 12 weeks as needed), or chlorambucil (10
mg administered by mouth daily for 6 weeks, then given daily on alternate months).<Reference refidx="13"/>  The
median survival for the phlebotomy group (13.9 years) and the radioisotope
phosphorous-32 group (11.8 years) was significantly better than that of the
chlorambucil group (8.9 years), primarily because of  excessive late deaths from
leukemia or other hematologic malignancies.<Reference refidx="13"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] 
Because of these concerns, many clinicians use hydroxyurea for patients who
require cytoreductive therapy that is caused by massive splenomegaly, a high phlebotomy requirement, or excessive thrombocytosis.<Reference refidx="13"/>   
</Para><Para id="_202">In a pooled analysis of 16 different trials, interferon-alpha therapy resulted in avoidance of phlebotomy in 50% of patients, with 80% of patients experiencing marked reduction of splenomegaly.<Reference refidx="14"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] Interferon posed problems of cost, side effects, and parenteral route of administration, but no cases of acute leukemia were seen in this analysis.  When patients are poorly compliant with phlebotomy or issues of massive splenomegaly, leukocytosis, or thrombocytosis supervene, treatment with interferon or pegylated interferon is considered for patients younger than 50 years (who are more likely to tolerate the side effects and benefit from a lack of transformation to leukemia), while hydroxyurea is considered for patients older than 50 years.<Reference refidx="2"/><Reference refidx="15"/></Para><Para id="_134"> In a Cochrane review of two randomized studies of 630 patients with no clear indication or contraindication for aspirin, those receiving 100 mg of aspirin versus placebo had reduction of fatal thrombotic events, but this benefit was not statistically significant (odds ratio, 0.20; 95% CI, .03–1.14).<Reference refidx="16"/> A retrospective review of 105 patients who underwent surgery documented 8% thromboembolism and 7% major hemorrhage with prior cytoreduction by phlebotomy and postoperative subcutaneous heparin in one half of the patients.<Reference refidx="17"/></Para><Para id="_164">Guidelines based on anecdotal reports have been developed for the management of pregnant patients with p. vera.<Reference refidx="3"/></Para><Para id="_72"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_48" Style="Arabic" Compact="No"><ListItem>Phlebotomy.<Reference refidx="10"/>
</ListItem><ListItem>Hydroxyurea (alone or with phlebotomy).<Reference refidx="12"/><Reference refidx="13"/></ListItem><ListItem>Interferon-alpha <Reference refidx="14"/><Reference refidx="18"/><Reference refidx="19"/> and pegylated interferon-alpha.<Reference refidx="20"/><Reference refidx="21"/></ListItem><ListItem>Rarely, chlorambucil or busulfan may be required, especially if interferon or hydroxyurea are not tolerated, as is often seen in patients older than 70 years.<Reference refidx="2"/></ListItem><ListItem>Low-dose aspirin (≤100 mg) daily, unless contraindicated by major bleeding or gastric intolerance.<Reference refidx="8"/><Reference refidx="16"/></ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_5_sid_3"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_5_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39350&amp;tt=1&amp;format=2&amp;cn=1">polycythemia vera</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_5_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19472396">Tefferi A, Thiele J, Vardiman JW: The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115 (17): 3842-7, 2009.</Citation><Citation idx="2" PMID="11830459" MedlineID="21818504">Streiff MB, Smith B, Spivak JL: The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 99 (4): 1144-9, 2002.</Citation><Citation idx="3" PMID="16029446">McMullin MF, Bareford D, Campbell P, et al.: Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 130 (2): 174-95, 2005.</Citation><Citation idx="4" PMID="17151367">Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355 (23): 2452-66, 2006.</Citation><Citation idx="5" PMID="15710945">Marchioli R, Finazzi G, Landolfi R, et al.: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23 (10): 2224-32, 2005.</Citation><Citation idx="6" PMID="15667529">Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128 (3): 275-90, 2005.</Citation><Citation idx="7" PMID="15877740">Chait Y, Condat B, Cazals-Hatem D, et al.: Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129 (4): 553-60, 2005.</Citation><Citation idx="8" PMID="17264301">Finazzi G, Barbui T: How I treat patients with polycythemia vera. Blood 109 (12): 5104-11, 2007.</Citation><Citation idx="9" PMID="23151052">Bonicelli G, Abdulkarim K, Mounier M, et al.: Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol 160 (2): 251-4, 2013.</Citation><Citation idx="10" PMID="3704665" MedlineID="86208202">Berk PD, Goldberg JD, Donovan PB, et al.: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23 (2): 132-43, 1986.</Citation><Citation idx="11" PMID="23216616">Marchioli R, Finazzi G, Specchia G, et al.: Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368 (1): 22-33, 2013.</Citation><Citation idx="12" PMID="9209196" MedlineID="97352938">Lamy T, Devillers A, Bernard M, et al.: Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 102 (1): 14-20, 1997.</Citation><Citation idx="13" PMID="3749925" MedlineID="86315914">Kaplan ME, Mack K, Goldberg JD, et al.: Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 23 (3): 167-71, 1986.</Citation><Citation idx="14" PMID="10803930">Lengfelder E, Berger U, Hehlmann R: Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79 (3): 103-9, 2000.</Citation><Citation idx="15" PMID="18650451">Kiladjian JJ, Cassinat B, Chevret S, et al.: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112 (8): 3065-72, 2008.</Citation><Citation idx="16" PMID="18425953">Squizzato A, Romualdi E, Middeldorp S: Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev  (2): CD006503, 2008.</Citation><Citation idx="17" PMID="17909074">Ruggeri M, Rodeghiero F, Tosetto A, et al.: Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111 (2): 666-71, 2008.</Citation><Citation idx="18" PMID="16804923">Silver RT: Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107 (3): 451-8, 2006.</Citation><Citation idx="19" PMID="16810616">Quintás-Cardama A, Kantarjian HM, Giles F, et al.: Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32 (4 Pt 2): 409-16, 2006.</Citation><Citation idx="20" PMID="19826111">Quintás-Cardama A, Kantarjian H, Manshouri T, et al.: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27 (32): 5418-24, 2009.</Citation><Citation idx="21" PMID="23782935">Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al.: Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 122 (6): 893-901, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_9"><SectMetaData><SpecificDiagnosis ref="CDR0000039357">primary myelofibrosis</SpecificDiagnosis></SectMetaData><Title>Primary Myelofibrosis</Title><SummarySection id="_73"><Title>Disease Overview</Title><Para id="_10">Primary myelofibrosis (also known as agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis, myelosclerosis with myeloid metaplasia, and idiopathic myelofibrosis) is characterized by splenomegaly, immature
peripheral blood granulocytes and erythrocytes, and teardrop-shaped red blood cells.<Reference refidx="1"/> 
In its early phase, the disease is characterized by elevated numbers of CD34-positive cells in the marrow, while the later phases involve marrow fibrosis with decreasing CD34 cells in the marrow and a corresponding increase in splenic and liver engorgement with CD34 cells.  </Para><Para id="_215">As distinguished from chronic
myelogenous leukemia (CML), primary myelofibrosis usually presents as follows:<Reference refidx="2"/></Para><ItemizedList id="_216" Style="bullet"><ListItem>A
white blood cell count smaller than 30,000/mm<Superscript>3</Superscript>.</ListItem><ListItem>Prominent
teardrops on peripheral smear.</ListItem><ListItem>Normocellular or hypocellular marrow with
moderate to marked fibrosis.</ListItem><ListItem>An absence of the Philadelphia chromosome or the <GeneName>BCR/ABL</GeneName> translocation.</ListItem><ListItem>Frequent positivity for the <GeneName>JAK2</GeneName> mutation.</ListItem></ItemizedList><Para id="_217"> In addition to the clonal
proliferation of a multipotent hematopoietic progenitor cell, an event common
to all chronic myeloproliferative neoplasms, myeloid metaplasia is
characterized by colonization of extramedullary sites such as the spleen or
liver.<Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_54">Most patients are older than 60 years at diagnosis, and 33%
of patients are asymptomatic at presentation.  Splenomegaly, sometimes massive,
is a characteristic finding.</Para><ItemizedList id="_117" Style="bullet"><ListTitle>Symptoms include:</ListTitle><ListItem>Splenic pain.</ListItem><ListItem>Early satiety.</ListItem><ListItem>Anemia.</ListItem><ListItem>Bone pain.</ListItem><ListItem>Fatigue.</ListItem><ListItem>Fever.</ListItem><ListItem>Night sweats.</ListItem><ListItem>Weight loss.</ListItem></ItemizedList><Para id="_211">(Refer to the PDQ summaries on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef>; <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>; <SummaryRef href="CDR0000062742" url="/about-cancer/treatment/side-effects/sexuality-fertility-women/hot-flashes-hp-pdq">Hot Flashes and Night Sweats</SummaryRef>; and <SummaryRef href="CDR0000276584" url="/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq">Nutrition</SummaryRef> for information on many of the symptoms listed above.)</Para><Para id="_203">The proposed World Health Organization criteria for the diagnosis of primary myelofibrosis requires all three major criteria and two minor criteria.<Reference refidx="5"/></Para><OrderedList id="_204" Style="Arabic"><ListTitle>Major Criteria</ListTitle><ListItem>Presence of megakaryocyte proliferation and atypia, usually accompanied by either reticulin and/or collagen fibrosis; or, in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (so-called prefibrotic cellular-phase disease).</ListItem><ListItem>Not meeting criteria for polycythemia vera (p. vera), CML, myelodysplastic syndrome, or other myeloid neoplasm.</ListItem><ListItem>Demonstration of <GeneName>JAK2</GeneName> 617V  greater than F or other clonal marker; or, in the absence of a clonal marker, no evidence of bone marrow fibrosis caused by an underlying inflammatory disease or another neoplastic disease. About 60% of patients with primary myelofibrosis carry a <GeneName>JAK2</GeneName> mutation, and about 5% to 10% of the patients have activating mutations in the thrombopoietin receptor gene, <GeneName>MPL</GeneName>. Almost 90% of the patients without <GeneName>JAK2</GeneName> or <GeneName>MPL</GeneName> carry a somatic mutation of the calreticulin gene, which is associated with a more indolent clinical course than is seen with <GeneName>JAK2</GeneName> or <GeneName>MPL</GeneName> mutations.<Reference refidx="6"/><Reference refidx="7"/></ListItem></OrderedList><OrderedList id="_205" Style="Arabic"><ListTitle>Minor Criteria</ListTitle><ListItem>Leukoerythroblastosis.</ListItem><ListItem>Increased serum level of lactate dehydrogenase.</ListItem><ListItem>Anemia.</ListItem><ListItem>Palpable splenomegaly.</ListItem></OrderedList><Para id="_118">The median
survival is 3.5 years  to 5.5 years, but patients younger than 55 years have a median survival of 11 years.<Reference refidx="3"/><Reference refidx="4"/> The major causes of death include:<Reference refidx="8"/> </Para><ItemizedList id="_212" Style="bullet"><ListItem>Progressive
marrow failure.</ListItem><ListItem>Transformation to acute nonlymphoblastic leukemia.</ListItem><ListItem>Infection.</ListItem><ListItem>Thrombohemorrhagic events.</ListItem><ListItem>Heart failure.</ListItem><ListItem>Portal hypertension.</ListItem></ItemizedList><Para id="_11">Fatal and nonfatal thrombosis was associated with age more than  60 years and <GeneName>JAK2</GeneName> 617V positivity in a multivariable analysis of 707 patients followed from 1973 to 2008.<Reference refidx="9"/> Bone marrow examination including cytogenetic testing may exclude other causes
of myelophthisis, such as CML, myelodysplastic
syndrome, metastatic cancer, lymphomas, and plasma cell disorders.<Reference refidx="4"/>  In acute
myelofibrosis, patients present with pancytopenia but no splenomegaly or
peripheral blood myelophthisis.  Peripheral blood or marrow monocytosis is
suggestive for myelodysplasia in this setting.
</Para><Para id="_12">There is no staging system for this disease.
</Para><Para id="_74">Prognostic factors include:<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></Para><ItemizedList id="_75" Style="bullet" Compact="No"><ListItem>Age 65 years or older.</ListItem><ListItem>Anemia (hemoglobin &lt;10 g/dL).</ListItem><ListItem>Constitutional symptoms:  fever, night sweats, or weight loss.</ListItem><ListItem>Leukocytosis (white blood cell count &gt;25 × 10<Superscript>9</Superscript>/L).</ListItem><ListItem>Circulating
blasts of at least 1%.</ListItem></ItemizedList><Para id="_13">Patients without any of the adverse features, excluding
age, have a median survival of more than 10 to 15 years, but the presence of any two 
of the adverse features lowers the median survival to less than 4 years.<Reference refidx="15"/><Reference refidx="16"/> International prognostic scoring systems incorporate the aforementioned prognostic factors.<Reference refidx="15"/><Reference refidx="17"/></Para><Para id="_239">Karyotype abnormalities can also affect prognosis. In a retrospective series, the 13q and 20q deletions and trisomy 9 correlated with improved survival and no leukemia transformation in comparison with the  worse prognosis with trisomy 8,  complex karyotype, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, or 11q23 rearrangement.<Reference refidx="9"/><Reference refidx="18"/> </Para></SummarySection><SummarySection id="_76"><Title>Treatment Overview</Title><Para id="_245">Asymptomatic low-risk patients (based on the aforementioned prognostic systems) should be followed with a watchful waiting approach. The development of symptomatic anemia, marked leukocytosis, drenching night sweats, weight loss, fever, or symptomatic splenomegaly would warrant therapeutic intervention.</Para><Para id="_79">The profound anemia  that develops in this disease usually requires red blood cell transfusion. 
Red blood cell survival is markedly decreased in some patients; this can
sometimes be treated with glucocorticoids.   Disease-associated anemia may occasionally respond to the following:<Reference refidx="4"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/> </Para><ItemizedList id="_213" Style="bullet" Compact="No"><ListItem>Erythropoietic growth factors. Erythropoietin and darbepoetin are less likely to help when patients are transfusion dependent or manifest a serum erythropoietin level greater than 125 U/L.<Reference refidx="22"/><Reference refidx="23"/></ListItem><ListItem>Prednisone (40–80 mg/day).</ListItem><ListItem>Danazol (600 mg/day).</ListItem><ListItem>Thalidomide (50 mg/day) ± prednisone.<Reference refidx="24"/> Patients on thalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.</ListItem><ListItem>Lenalidomide (10 mg/day) ± prednisone.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/> In the presence of del(5q), lenalidomide with or without prednisone, can reverse anemia and splenomegaly in most patients.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/> However, patients on lenalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.</ListItem><ListItem>Pomalidomide.<Reference refidx="28"/> Patients on pomalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.</ListItem></ItemizedList><Para id="_270">Ruxolitinib, an inhibitor of JAK1 and JAK2, can reduce the splenomegaly and debilitating symptoms of weight loss, fatigue, and night sweats for patients with <GeneName>JAK2</GeneName>-positive or <GeneName>JAK2</GeneName>-negative primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–p. vera myelofibrosis.<Reference refidx="29"/></Para><Para id="_243"> In two prospective, randomized trials, 528 higher-risk patients were randomly assigned to ruxolitinib or to either placebo (<ProtocolRef href="CDR0000759480" nct_id="NCT00952289">COMFORT-I</ProtocolRef> [NCT00952289])  or best available therapy (<ProtocolRef href="CDR0000759479" nct_id="NCT00934544">COMFORT-II</ProtocolRef> [NCT00934544]). At 48 weeks, patients on ruxolitinib had a decrease of 30% to 40% in mean spleen volume compared with an increase of 7% to 8% in the control patients.<Reference refidx="30"/>[<LOERef href="CDR0000587983">Level of evidence: 1iiDiv</LOERef>]; <Reference refidx="31"/>[<LOERef href="CDR0000587981">Level of evidence: 1iDiv</LOERef>] Ruxolitinib also improved overall quality-of-life measures, with low toxic effects in both studies,  but with no benefit in overall survival in the initial reports. Additional follow-up in both studies  (1 year in COMFORT-I and 2 years in COMFORT-II) showed  a survival benefit among ruxolitinib-treated patients compared with control patients (COMFORT-I hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.36–0.95; and COMFORT-II HR, 0.48; 95% CI, 0.28–0.85).<Reference refidx="32"/><Reference refidx="33"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Clinical benefits were observed across a wide variety of clinical subgroups.<Reference refidx="34"/><Reference refidx="35"/> Discontinuation of ruxolitinib results in a rapid worsening of splenomegaly and the recurrence of systemic symptoms.<Reference refidx="30"/><Reference refidx="31"/><Reference refidx="36"/> Ruxolitinib does not reverse bone marrow fibrosis or induce histologic or cytogenetic remissions.  More selective JAK inhibitors are currently being evaluated in clinical trials.<Reference refidx="37"/><Reference refidx="38"/> </Para><Para id="_80">Painful splenomegaly can be treated
temporarily with ruxolitinib, hydroxyurea, thalidomide, lenalidomide, cladribine, or radiation therapy,
but sometimes requires splenectomy.<Reference refidx="21"/><Reference refidx="39"/><Reference refidx="40"/>  The decision to perform splenectomy
represents a weighing of the benefits (i.e., reduction of symptoms, decreased portal
hypertension, and less need for red blood cell transfusions lasting for 1 to 2 years) versus the debits
(i.e., postoperative mortality of 10% and morbidity of 30% caused by  infection,
bleeding, or thrombosis; no benefit for thrombocytopenia; and accelerated
progression to the  blast-crisis phase  that was seen by some investigators but not others).<Reference refidx="4"/><Reference refidx="39"/> 
    </Para><Para id="_244">After splenectomy, many physicians use anticoagulation therapy for 4 to 6 weeks to reduce portal vein thrombosis,  and hydroxyurea can be utilized to reduce high platelet levels (&gt;1 million).<Reference refidx="41"/> However, data from a retrospective review of 150 patients who underwent surgery provided documentation that 8% of the patients had a thromboembolism and 7% had a major hemorrhage with prior cytoreduction and postoperative subcutaneous heparin used in one-half of the patients.<Reference refidx="42"/></Para><Para id="_234">Hydroxyurea is useful in patients with splenomegaly but may have a potential leukemogenic effect.<Reference refidx="4"/>  In patients with
thrombocytosis and hepatomegaly after splenectomy, cladribine has shown
responses as an alternative to hydroxyurea.<Reference refidx="43"/> The use of interferon-alpha can result in hematologic responses, including
reduction in spleen size in 30% to 50% of patients, though many patients do
not tolerate this medication.<Reference refidx="44"/><Reference refidx="45"/>  Favorable responses to thalidomide and lenalidomide have been reported in about 20% to 60% of patients.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="46"/><Reference refidx="47"/><Reference refidx="48"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</Para><Para id="_235">A response defined as 50% reduction of splenomegaly or development of transfusion independence was attained by one-third of 34 symptomatic patients using tipifarnib.<Reference refidx="49"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] A more aggressive approach involves
allogeneic peripheral stem cell or bone marrow transplantation when a suitable
donor is available.<Reference refidx="50"/><Reference refidx="51"/><Reference refidx="52"/><Reference refidx="53"/><Reference refidx="54"/><Reference refidx="55"/> Allogeneic stem cell transplantation is the only potentially curative treatment available, but the associated morbidity and mortality limit its use to younger, high-risk patients.<Reference refidx="53"/><Reference refidx="56"/> Detection of the <GeneName>JAK2</GeneName>  mutation after transplantation is associated with a worse prognosis.<Reference refidx="57"/></Para><Para id="_82"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_49" Style="Arabic"><ListItem>Ruxolitinib.<Reference refidx="30"/><Reference refidx="31"/><Reference refidx="36"/><Reference refidx="37"/></ListItem><ListItem>Clinical trials involving other JAK2 inhibitors.</ListItem><ListItem>Hydroxyurea.<Reference refidx="3"/><Reference refidx="4"/>
</ListItem><ListItem>Allogeneic peripheral stem cell or bone marrow transplantation.<Reference refidx="51"/><Reference refidx="52"/><Reference refidx="53"/><Reference refidx="54"/><Reference refidx="55"/>
</ListItem><ListItem>Thalidomide.<Reference refidx="19"/><Reference refidx="24"/><Reference refidx="46"/><Reference refidx="47"/><Reference refidx="48"/><Reference refidx="50"/></ListItem><ListItem>Lenalidomide.<Reference refidx="21"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="48"/></ListItem><ListItem>Pomalidomide.<Reference refidx="28"/></ListItem><ListItem>Splenectomy.<Reference refidx="39"/><Reference refidx="58"/></ListItem><ListItem>Splenic radiation therapy or radiation to sites of symptomatic extramedullary hematopoiesis (e.g., large lymph nodes, cord compression).<Reference refidx="4"/></ListItem><ListItem>Cladribine.<Reference refidx="43"/></ListItem><ListItem>Interferon-alpha.<Reference refidx="44"/><Reference refidx="45"/></ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_9_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_9_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39357&amp;tt=1&amp;format=2&amp;cn=1">primary myelofibrosis</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_9_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15565565">Hennessy BT, Thomas DA, Giles FJ, et al.: New approaches in the treatment of myelofibrosis. Cancer 103 (1): 32-43, 2005.</Citation><Citation idx="2" PMID="17151367">Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355 (23): 2452-66, 2006.</Citation><Citation idx="3" PMID="10561375" MedlineID="20030104">Barosi G: Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (9): 2954-70, 1999.</Citation><Citation idx="4" PMID="10781623" MedlineID="20228762">Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342 (17): 1255-65, 2000.</Citation><Citation idx="5" PMID="19472396">Tefferi A, Thiele J, Vardiman JW: The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115 (17): 3842-7, 2009.</Citation><Citation idx="6" PMID="24325356">Klampfl T, Gisslinger H, Harutyunyan AS, et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369 (25): 2379-90, 2013.</Citation><Citation idx="7" PMID="24325359">Nangalia J, Massie CE, Baxter EJ, et al.: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369 (25): 2391-405, 2013.</Citation><Citation idx="8" PMID="16344424">Chim CS, Kwong YL, Lie AK, et al.: Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165 (22): 2651-8, 2005 Dec 12-26.</Citation><Citation idx="9" PMID="19901264">Hussein K, Pardanani AD, Van Dyke DL, et al.: International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115 (3): 496-9, 2010.</Citation><Citation idx="10" PMID="9722294" MedlineID="98387749">Cervantes F, Barosi G, Demory JL, et al.: Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102 (3): 684-90, 1998.</Citation><Citation idx="11" PMID="16396767">Strasser-Weippl K, Steurer M, Kees M, et al.: Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 47 (3): 441-50, 2006.</Citation><Citation idx="12" PMID="16396759">Tefferi A: Survivorship and prognosis in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 47 (3): 379-80, 2006.</Citation><Citation idx="13" PMID="19786661">Tam CS, Kantarjian H, Cortes J, et al.: Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 27 (33): 5587-93, 2009.</Citation><Citation idx="14" PMID="20308601">Morel P, Duhamel A, Hivert B, et al.: Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 115 (22): 4350-5, 2010.</Citation><Citation idx="15" PMID="18988864">Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 (13): 2895-901, 2009.</Citation><Citation idx="16" PMID="22212965">Tefferi A, Lasho TL, Jimma T, et al.: One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 87 (1): 25-33, 2012.</Citation><Citation idx="17" PMID="21149668">Gangat N, Caramazza D, Vaidya R, et al.: DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29 (4): 392-7, 2011.</Citation><Citation idx="18" PMID="20944670">Caramazza D, Begna KH, Gangat N, et al.: Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25 (1): 82-8, 2011.</Citation><Citation idx="19" PMID="12613516">Giovanni B, Michelle E, Letizia C, et al.: Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 43 (12): 2301-7, 2002.</Citation><Citation idx="20" PMID="14752066">Marchetti M, Barosi G, Balestri F, et al.: Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22 (3): 424-31, 2004.</Citation><Citation idx="21" PMID="16609064">Tefferi A, Cortes J, Verstovsek S, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108 (4): 1158-64, 2006.</Citation><Citation idx="22" PMID="15521916">Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al.: Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 127 (4): 399-403, 2004.</Citation><Citation idx="23" PMID="19366369">Huang J, Tefferi A: Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 83 (2): 154-5, 2009.</Citation><Citation idx="24" PMID="16583431">Thomas DA, Giles FJ, Albitar M, et al.: Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106 (9): 1974-84, 2006.</Citation><Citation idx="25" PMID="17460705">Tefferi A, Lasho TL, Mesa RA, et al.: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 21 (8): 1827-8, 2007.</Citation><Citation idx="26" PMID="20651074">Mesa RA, Yao X, Cripe LD, et al.: Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 116 (22): 4436-8, 2010.</Citation><Citation idx="27" PMID="19720904">Quintás-Cardama A, Kantarjian HM, Manshouri T, et al.: Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27 (28): 4760-6, 2009.</Citation><Citation idx="28" PMID="21052089">Begna KH, Mesa RA, Pardanani A, et al.: A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25 (2): 301-4, 2011.</Citation><Citation idx="29" PMID="20843246">Verstovsek S, Kantarjian H, Mesa RA, et al.: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363 (12): 1117-27, 2010.</Citation><Citation idx="30" PMID="22375970">Harrison C, Kiladjian JJ, Al-Ali HK, et al.: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (9): 787-98, 2012.</Citation><Citation idx="31" PMID="22375971">Verstovsek S, Mesa RA, Gotlib J, et al.: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366 (9): 799-807, 2012.</Citation><Citation idx="32" PMID="24038026">Verstovsek S, Mesa RA, Gotlib J, et al.: Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98 (12): 1865-71, 2013.</Citation><Citation idx="33" PMID="24174625">Cervantes F, Vannucchi AM, Kiladjian JJ, et al.: Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122 (25): 4047-53, 2013.</Citation><Citation idx="34" PMID="23570800">Mascarenhas J, Hoffman R: A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121 (24): 4832-7, 2013.</Citation><Citation idx="35" PMID="23480528">Verstovsek S, Mesa RA, Gotlib J, et al.: The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161 (4): 508-16, 2013.</Citation><Citation idx="36" PMID="21995409">Tefferi A, Litzow MR, Pardanani A: Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365 (15): 1455-7, 2011.</Citation><Citation idx="37" PMID="21220594">Verstovsek S: Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Oncol 29 (7): 781-3, 2011.</Citation><Citation idx="38" PMID="22279053">Tefferi A: JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119 (12): 2721-30, 2012.</Citation><Citation idx="39" PMID="9572998" MedlineID="98241405">Barosi G, Ambrosetti A, Centra A, et al.: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 91 (10): 3630-6, 1998.</Citation><Citation idx="40" PMID="21848363">Lavrenkov K, Krepel-Volsky S, Levi I, et al.: Low dose palliative radiotherapy for splenomegaly in hematologic disorders. Leuk Lymphoma 53 (3): 430-4, 2012.</Citation><Citation idx="41" PMID="16770787">Mesa RA, Nagorney DS, Schwager S, et al.: Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107 (2): 361-70, 2006.</Citation><Citation idx="42" PMID="17909074">Ruggeri M, Rodeghiero F, Tosetto A, et al.: Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111 (2): 666-71, 2008.</Citation><Citation idx="43" PMID="10733489" MedlineID="20197869">Tefferi A, Mesa RA, Nagorney DM, et al.: Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95 (7): 2226-33, 2000.</Citation><Citation idx="44" PMID="8574158" MedlineID="96116922">Sacchi S: The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leuk Lymphoma 19 (1-2): 13-20, 1995.</Citation><Citation idx="45" PMID="9740087" MedlineID="98410803">Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 83 (6): 1205-13, 1998.</Citation><Citation idx="46" PMID="14962263">Strupp C, Germing U, Scherer A, et al.: Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 72 (1): 52-7, 2004.</Citation><Citation idx="47" PMID="15244384">Mesa RA, Elliott MA, Schroeder G, et al.: Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 79 (7): 883-9, 2004.</Citation><Citation idx="48" PMID="21622644">Jabbour E, Thomas D, Kantarjian H, et al.: Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118 (4): 899-902, 2011.</Citation><Citation idx="49" PMID="17581608">Mesa RA, Camoriano JK, Geyer SM, et al.: A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 21 (9): 1964-70, 2007.</Citation><Citation idx="50" PMID="10216077" MedlineID="99233644">Guardiola P, Anderson JE, Bandini G, et al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93 (9): 2831-8, 1999.</Citation><Citation idx="51" PMID="12920019">Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (12): 3912-8, 2003.</Citation><Citation idx="52" PMID="12815476">Daly A, Song K, Nevill T, et al.: Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 32 (1): 35-40, 2003.</Citation><Citation idx="53" PMID="22700718">Gupta V, Hari P, Hoffman R: Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 120 (7): 1367-79, 2012.</Citation><Citation idx="54" PMID="19812383">Kröger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114 (26): 5264-70, 2009.</Citation><Citation idx="55" PMID="21552298">Abelsson J, Merup M, Birgegård G, et al.: The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 47 (3): 380-6, 2012.</Citation><Citation idx="56" PMID="22280409">Alchalby H, Yunus DR, Zabelina T, et al.: Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 157 (1): 75-85, 2012.</Citation><Citation idx="57" PMID="20489052">Alchalby H, Badbaran A, Zabelina T, et al.: Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116 (18): 3572-81, 2010.</Citation><Citation idx="58" PMID="9375753" MedlineID="98041601">Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99 (2): 352-7, 1997.</Citation></ReferenceSection></SummarySection><SummarySection id="_14"><SectMetaData><SpecificDiagnosis ref="CDR0000039361">essential thrombocythemia</SpecificDiagnosis></SectMetaData><Title>Essential Thrombocythemia</Title><SummarySection id="_87"><Title>Disease Overview</Title><Para id="_207">The proposed revised World Health Organization (WHO) criteria for the diagnosis of essential thrombocythemia requires the following criteria:<Reference refidx="1"/></Para><OrderedList id="_208" Style="Arabic" Compact="No"><ListTitle>Criteria</ListTitle><ListItem>Sustained platelet count of at least 450 × 10<Superscript>9</Superscript>/L.</ListItem><ListItem>Bone marrow biopsy showing predominant proliferation of enlarged mature megakaryocytes; no significant increase of granulocytic or erythroid precursors. This finding distinguishes essential thrombocythemia from another entity with thrombocytosis, namely prefibrotic primary myelofibrosis, which is identified by increased granulocytic or erythroid precursors, atypical megakaryocytes, and increased bone marrow cellularity.  <Para id="_260">Patients with prefibrotic primary myelofibrosis have a worse survival than patients with essential thrombocythemia because of  an  increased progression to myelofibrosis and increased progression to acute myelogenous leukemia.<Reference refidx="2"/><Reference refidx="3"/> Patients with prefibrotic primary myelofibrosis may also have a higher tendency to bleed, which can be exacerbated by low-dose aspirin.<Reference refidx="4"/></Para></ListItem><ListItem>Not meeting criteria for polycythemia vera (p. vera), primary myelofibrosis, chronic myelogenous leukemia, myelodysplastic syndrome, or other myeloid neoplasm.</ListItem><ListItem>Demonstration of <GeneName>JAK2</GeneName> V617F mutation or myeloproliferative leukemia (MPL) exon 10 mutation.<Reference refidx="5"/> In the absence of a clonal marker, there must be no evidence for reactive thrombocytosis.  In particular, with a decreased serum ferritin, there must be no increase in hemoglobin level to p. vera range with iron replacement therapy. In the presence of a <GeneName>JAK2</GeneName> or <GeneName>MPL</GeneName> mutation and exclusion of other myeloproliferative or myelodysplastic features, a bone marrow aspirate/biopsy may not be mandatory for a diagnosis.<Reference refidx="6"/> About 60% of patients with essential thrombocythemia carry a <GeneName>JAK2</GeneName> mutation, and about 5% to 10% of the patients have activating mutations in the thrombopoietin receptor gene, <GeneName>MPL</GeneName>. About 70% of the patients without <GeneName>JAK2</GeneName> or <GeneName>MPL</GeneName> carry a somatic mutation of the calreticulin gene, which is associated with a more indolent clinical course than is seen with <GeneName>JAK2</GeneName> or <GeneName>MPL</GeneName> mutations.<Reference refidx="7"/><Reference refidx="8"/></ListItem></OrderedList><Para id="_16">Patients older than 60 years or those with a prior thrombotic episode 
or with leukocytosis have as much as a 25% chance of developing cerebral, cardiac, or peripheral arterial
thromboses and, less often, a chance of developing a pulmonary embolism or deep
venous thrombosis.<Reference refidx="2"/><Reference refidx="9"/><Reference refidx="10"/>  Similar to the other myeloproliferative syndromes,
conversion to acute leukemia is found in a small percentage of patients (&lt;10%) with long-term follow-up.
</Para><Para id="_17">There is no staging system for this disease.
</Para><Para id="_88">Untreated essential thrombocythemia means that a patient is newly diagnosed and has had no prior treatment except supportive care. </Para></SummarySection><SummarySection id="_89"><Title>Treatment Overview</Title><Para id="_91">Controversy is considerable regarding whether asymptomatic patients with
essential thrombocythemia require treatment.  In
a case-controlled, observational study of 65 low-risk patients (&lt;60 years of
age, platelet count &lt;1,500 × 10<Superscript>9</Superscript>/L, and no history of thrombosis or hemorrhage)
with a median follow-up of 4.1 years, the thrombotic risk of 1.91 cases per 100
patient years and hemorrhagic risk of 1.12 cases per 100 patient years was not
increased any more than in the normal controls.<Reference refidx="11"/></Para><OrderedList id="_275" Style="Arabic" Compact="No"><ListItem>A randomized trial of patients
with essential thrombocythemia and a high risk of thrombosis compared treatment
with hydroxyurea titrated to attain a platelet count below 600,000/mm<Superscript>3</Superscript> with a control group that received no therapy.  Hydroxyurea was
found to be effective in preventing thrombotic episodes (4% vs.
24%).<Reference refidx="9"/>[<LOERef href="CDR0000587983">Level of evidence: 1iiDiv</LOERef>]  A retrospective analysis of this trial
found that antiplatelet drugs had no significant influence on the outcome. Resistance to hydroxyurea is defined as a platelet count of greater than 600,000/mcL after 3 months of at least 2 g per day of hydroxyurea or a platelet count greater than  400,000/µL and a white blood count  of less than 2,500/µL or a hemoglobin less than 10 g/dL at any dose of hydroxyurea.<Reference refidx="12"/></ListItem><ListItem>A prospective, randomized trial in the United Kingdom (UK) of 809 patients  compared hydroxyurea plus aspirin with anagrelide plus aspirin.<Reference refidx="13"/>  Although the platelet-lowering effect was equivalent, the anagrelide group had significantly more thrombotic and hemorrhagic events (hazard ratio [HR], 1.57; <Emphasis>P</Emphasis> = .03) and more myelofibrosis (HR,  2.92; <Emphasis>P</Emphasis> = .01). No differences were seen for subsequent myelodysplasia or acute leukemia in this trial.<Reference refidx="14"/>[<LOERef href="CDR0000632558">Level of evidence: 1iiD</LOERef>]</ListItem><ListItem>Another prospective, randomized trial also compared hydroxyurea and anagrelide in 259 previously    untreated and high-risk patients.<Reference refidx="15"/> In this central European trial, the diagnosis of essential thrombocythemia was made by the WHO recommendations, not by the Polycythemia Vera Study Group criteria as in the UK study. This means that patients with leukocytosis and a diagnosis of early prefibrotic myelofibrosis (both groups with much higher rates of thrombosis) were excluded from the central European trial. In this analysis, there were no differences in outcome for thrombotic or hemorrhagic events.<Reference refidx="15"/>[<LOERef href="CDR0000632558">Level of evidence: 1iiD</LOERef>] </ListItem></OrderedList><Para id="_276">These three randomized, prospective trials establish the efficacy and safety for the use of hydroxyurea for patients with high-risk essential thrombocythemia (age &gt;60 years + platelet count &gt;1,000 × 10<Superscript>9</Superscript>/L or &gt;1,500 × 10<Superscript>9</Superscript>/L). For patients diagnosed by WHO standards (excluding patients with leukocytosis and prefibrotic myelofibrosis by bone marrow biopsy), anagrelide represents a reasonable alternative therapy. The addition of aspirin to cytoreductive therapies like hydroxyurea or anagrelide remains controversial, but a retrospective anecdotal report suggested reduction in thrombosis for patients older than 60 years.<Reference refidx="16"/> </Para><Para id="_277">Many clinicians use hydroxyurea or platelet apheresis prior to
elective surgery to reduce the platelet count and to prevent postoperative
thromboembolism.  No prospective or randomized trials 
document the value of this approach.</Para><Para id="_241">Among low-risk patients (defined as age ≤60 years with no prior thrombotic episodes), a retrospective review of 300 patients showed benefit for antiplatelet agents in reducing venous thrombosis in <GeneName>JAK2</GeneName>-positive cases and in reducing arterial thrombosis in patients with cardiovascular risk factors.<Reference refidx="17"/> Balancing the risks and benefits of aspirin for low-risk patients can be difficult.<Reference refidx="18"/> In an extrapolation of the data from trials of  p. vera, low-dose aspirin to prevent vascular events has been suggested, but there are no data from clinical trials to address this issue.<Reference refidx="19"/></Para><Para id="_93"><Strong>Treatment options:</Strong></Para><OrderedList id="_50" Style="Arabic" Compact="No"><ListItem>No treatment, unless complications develop, if patients are asymptomatic, younger than 60 years, and have a platelet count of  less than 1,500 × 10<Superscript>9</Superscript>/L.</ListItem><ListItem>Hydroxyurea.<Reference refidx="9"/>
</ListItem><ListItem>Interferon-alpha <Reference refidx="20"/><Reference refidx="21"/> or pegylated interferon-alpha.<Reference refidx="22"/><Reference refidx="23"/></ListItem><ListItem>Anagrelide.<Reference refidx="14"/><Reference refidx="24"/></ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_14_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_14_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39361&amp;tt=1&amp;format=2&amp;cn=1">essential thrombocythemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_14_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19472396">Tefferi A, Thiele J, Vardiman JW: The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115 (17): 3842-7, 2009.</Citation><Citation idx="2" PMID="22740446">Passamonti F, Thiele J, Girodon F, et al.: A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120 (6): 1197-201, 2012.</Citation><Citation idx="3" PMID="22700720">Barbui T, Thiele J, Carobbio A, et al.: Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 120 (3): 569-71, 2012.</Citation><Citation idx="4" PMID="21926959">Finazzi G, Carobbio A, Thiele J, et al.: Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26 (4): 716-9, 2012.</Citation><Citation idx="5" PMID="17151367">Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355 (23): 2452-66, 2006.</Citation><Citation idx="6" PMID="20331456">Harrison CN, Bareford D, Butt N, et al.: Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149 (3): 352-75, 2010.</Citation><Citation idx="7" PMID="24325356">Klampfl T, Gisslinger H, Harutyunyan AS, et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369 (25): 2379-90, 2013.</Citation><Citation idx="8" PMID="24325359">Nangalia J, Massie CE, Baxter EJ, et al.: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369 (25): 2391-405, 2013.</Citation><Citation idx="9" PMID="7700286" MedlineID="95214679">Cortelazzo S, Finazzi G, Ruggeri M, et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332 (17): 1132-6, 1995.</Citation><Citation idx="10" PMID="22375970">Harrison C, Kiladjian JJ, Al-Ali HK, et al.: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (9): 787-98, 2012.</Citation><Citation idx="11" PMID="9858229" MedlineID="99073940">Ruggeri M, Finazzi G, Tosetto A, et al.: No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 103 (3): 772-7, 1998.</Citation><Citation idx="12" PMID="17251900">Barosi G, Besses C, Birgegard G, et al.: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21 (2): 277-80, 2007.</Citation><Citation idx="13" PMID="16000354">Harrison CN, Campbell PJ, Buck G, et al.: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (1): 33-45, 2005.</Citation><Citation idx="14">Green A, Campbell P, Buck G: The Medical Research Council PT1 trial in essential thrombocythemia. [Abstract] Blood  104 (11): A-6, 2004.</Citation><Citation idx="15" PMID="23315161">Gisslinger H, Gotic M, Holowiecki J, et al.: Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121 (10): 1720-8, 2013.</Citation><Citation idx="16" PMID="23577924">Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, et al.: Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol 161 (6): 865-71, 2013.</Citation><Citation idx="17" PMID="20508163">Alvarez-Larrán A, Cervantes F, Pereira A, et al.: Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116 (8): 1205-10; quiz 1387, 2010.</Citation><Citation idx="18" PMID="21056468">Harrison C, Barbui T: Aspirin in low-risk essential thrombocythemia, not so simple after all? Leuk Res 35 (3): 286-9, 2011.</Citation><Citation idx="19" PMID="22051530">Finazzi G: How to manage essential thrombocythemia. Leukemia 26 (5): 875-82, 2012.</Citation><Citation idx="20" PMID="8574158" MedlineID="96116922">Sacchi S: The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leuk Lymphoma 19 (1-2): 13-20, 1995.</Citation><Citation idx="21" PMID="9740087" MedlineID="98410803">Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 83 (6): 1205-13, 1998.</Citation><Citation idx="22" PMID="19826111">Quintás-Cardama A, Kantarjian H, Manshouri T, et al.: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27 (32): 5418-24, 2009.</Citation><Citation idx="23" PMID="23782935">Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al.: Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 122 (6): 893-901, 2013.</Citation><Citation idx="24" PMID="1731512" MedlineID="92117061">Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med 92 (1): 69-76, 1992.</Citation></ReferenceSection></SummarySection><SummarySection id="_95"><SectMetaData><SpecificDiagnosis ref="CDR0000276485">chronic neutrophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Chronic Neutrophilic Leukemia (CNL)</Title><SummarySection id="_96"><Title>Disease Overview</Title><Para id="_97">CNL is a rare chronic myeloproliferative neoplasm of unknown etiology, characterized by sustained peripheral blood neutrophilia (&gt;25 × 10<Superscript>9</Superscript>/L) and hepatosplenomegaly.<Reference refidx="1"/><Reference refidx="2"/>  The bone marrow is hypercellular.  No significant dysplasia is in any of the cell lineages, and bone marrow fibrosis is uncommon.<Reference refidx="1"/><Reference refidx="2"/>  Cytogenetic studies are normal in nearly 90% of the patients.  In the remaining patients, clonal karyotypic abnormalities may include +8, +9, del (20q) and del (11q).<Reference refidx="1"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  There is no Philadelphia chromosome or <GeneName>BCR/ABL</GeneName> fusion gene.  CNL is a slowly progressive disorder, and the survival of patients is variable, ranging from 6 months to more than 20 years.</Para></SummarySection><SummarySection id="_98"><Title>Treatment Overview</Title><Para id="_99">Until the last few years, the treatment of CNL focused on disease control rather than cure. Once the disease progressed to a more aggressive leukemia, there was typically little chance of obtaining a long-lasting remission because of  the older age of most patients as well as the acquisition of multiple poor prognostic cytogenetic abnormalities.  Allogeneic bone marrow transplantation represents a potentially curative treatment modality in the management of this disorder.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>  Varying success has been reported with the use of traditional chemotherapies including hydroxyurea and interferon.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_TrialSearch_95_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_95_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=276485&amp;tt=1&amp;format=2&amp;cn=1">chronic neutrophilic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_95_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Imbert M, Bain B, Pierre R, et al.: Chronic neutrophilic leukemia. In: Jaffe ES, Harris NL, Stein H, et al., eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. World Health Organization Classification of Tumours, 3, pp 27-8.</Citation><Citation idx="2" PMID="8148416" MedlineID="94198333">Zittoun R, Réa D, Ngoc LH, et al.: Chronic neutrophilic leukemia. A study of four cases. Ann Hematol 68 (2): 55-60, 1994.</Citation><Citation idx="3" PMID="9557623" MedlineID="98216701">Froberg MK, Brunning RD, Dorion P, et al.: Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia 12 (4): 623-6, 1998.</Citation><Citation idx="4" PMID="9495373" MedlineID="98154761">Yanagisawa K, Ohminami H, Sato M, et al.: Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. Am J Hematol 57 (3): 221-4, 1998.</Citation><Citation idx="5" PMID="8980264" MedlineID="97134704">Matano S, Nakamura S, Kobayashi K, et al.: Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: cytogenetic findings in chronic neutrophilic leukemia. Am J Hematol 54 (1): 72-5, 1997.</Citation><Citation idx="6" PMID="12481908" MedlineID="22369425">Piliotis E, Kutas G, Lipton JH: Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leuk Lymphoma 43 (10): 2051-4, 2002.</Citation><Citation idx="7" PMID="8826884" MedlineID="96424361">Hasle H, Olesen G, Kerndrup G, et al.: Chronic neutrophil leukaemia in adolescence and young adulthood. Br J Haematol 94 (4): 628-30, 1996.</Citation><Citation idx="8" PMID="12401827" MedlineID="22289451">Böhm J, Schaefer HE: Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol 55 (11): 862-4, 2002.</Citation><Citation idx="9" PMID="11243396" MedlineID="21132844">Elliott MA, Dewald GW, Tefferi A, et al.: Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia 15 (1): 35-40, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_101"><SectMetaData><SpecificDiagnosis ref="CDR0000276487">chronic eosinophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Chronic Eosinophilic Leukemia (CEL)</Title><SummarySection id="_102"><Title>Disease Overview</Title><Para id="_103">CEL is a chronic myeloproliferative neoplasm of unknown etiology in which a clonal proliferation of eosinophilic precursors results in persistently increased numbers of eosinophils in the blood, bone marrow, and peripheral tissues.  In CEL, the eosinophil count is greater than or equal to 1.5 × 10<Superscript>9</Superscript>/L in the blood.<Reference refidx="1"/> To make a diagnosis of CEL, there should be evidence for clonality of the eosinophils or an increase in blasts in the blood or bone marrow.  In many cases, however, it is impossible to prove clonality of the eosinophils, in which case, if there is no increase in blast cells, the diagnosis of idiopathic hypereosinophilic syndrome (HES) is preferred.  Because of the difficulty in distinguishing CEL from HES, the true incidence of these diseases is unknown, although they are rare.  In about 10% of patients, eosinophilia is detected incidentally.  In others, the constitutional symptoms found  include:<Reference refidx="1"/><Reference refidx="2"/> </Para><ItemizedList id="_218" Style="bullet"><ListItem>Fever.</ListItem><ListItem>Fatigue.</ListItem><ListItem>Cough.</ListItem><ListItem>Angioedema.</ListItem><ListItem>Muscle pains.</ListItem><ListItem>Pruritus.</ListItem><ListItem>Diarrhea.</ListItem></ItemizedList><Para id="_219">    No single or specific cytogenetic or molecular genetic abnormality has been identified in CEL.</Para><Para id="_236">(Refer to the PDQ summaries on <SummaryRef href="CDR0000062742" url="/about-cancer/treatment/side-effects/sexuality-fertility-women/hot-flashes-hp-pdq">Hot Flashes and Night Sweats</SummaryRef>; <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>; <SummaryRef href="CDR0000352186" url="/about-cancer/treatment/side-effects/cardiopulmonary-hp-pdq">Cardiopulmonary Syndromes</SummaryRef>; <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef>; <SummaryRef href="CDR0000062748" url="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq">Pruritus</SummaryRef>; and <SummaryRef href="CDR0000062736" url="/about-cancer/treatment/side-effects/constipation/GI-complications-hp-pdq">Gastrointestinal Complications</SummaryRef> for information on many of the symptoms listed above.)</Para></SummarySection><SummarySection id="_104"><Title>Treatment Overview</Title><Para id="_105">The optimal treatment of CEL remains uncertain, partially on account of  the rare incidence of this chronic myeloproliferative neoplasm and the variable clinical course, which can range from cases with decades of stable disease to cases with rapid progression to acute leukemia.  Case reports suggest that treatment options include bone marrow transplantation and interferon-alpha.<Reference refidx="3"/><Reference refidx="4"/> </Para><Para id="_221">Treatment of HES has included the following:<Reference refidx="5"/><Reference refidx="6"/></Para><ItemizedList id="_222" Style="bullet"><ListItem>Corticosteroids.</ListItem><ListItem>Chemotherapeutic agents such as hydroxyurea, cyclophosphamide, and vincristine.</ListItem><ListItem>Interferon-alpha.</ListItem></ItemizedList><Para id="_223">Case reports suggest symptomatic responses  to imatinib mesylate for patients with HES who have not responded to conventional options.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]   Imatinib mesylate acts as an inhibitor of a novel fusion tyrosine kinase, FIP1L1-PDGFR alpha fusion tyrosine kinase, which results as a consequence of interstitial chromosomal deletion.<Reference refidx="6"/><Reference refidx="9"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] HES with the FIP1L1-PDGFR alpha fusion tyrosine kinase translocation has been shown to respond to  low-dose imatinib mesylate.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_TrialSearch_101_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_101_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=276487&amp;tt=1&amp;format=2&amp;cn=1">chronic eosinophilic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_101_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Bain B, Pierre P, Imbert M, et al.: Chronic eosinophillic leukaemia and the hypereosinophillic syndrome. In: Jaffe ES, Harris NL, Stein H, et al., eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. World Health Organization Classification of Tumours, 3, pp 29-31.</Citation><Citation idx="2" PMID="8180373" MedlineID="94235839">Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood 83 (10): 2759-79, 1994.</Citation><Citation idx="3" PMID="10037016" MedlineID="99154620">Basara N, Markova J, Schmetzer B, et al.: Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Leuk Lymphoma 32 (1-2): 189-93, 1998.</Citation><Citation idx="4" PMID="9625582" MedlineID="98287264">Yamada O, Kitahara K, Imamura K, et al.: Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 58 (2): 137-41, 1998.</Citation><Citation idx="5" PMID="7944072" MedlineID="95030681">Butterfield JH, Gleich GJ: Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 121 (9): 648-53, 1994.</Citation><Citation idx="6" PMID="15070659">Gotlib J, Cools J, Malone JM 3rd, et al.: The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103 (8): 2879-91, 2004.</Citation><Citation idx="7" PMID="12047970" MedlineID="22043547">Gleich GJ, Leiferman KM, Pardanani A, et al.: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (9317): 1577-8, 2002.</Citation><Citation idx="8" PMID="12127565" MedlineID="22126542">Ault P, Cortes J, Koller C, et al.: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26 (9): 881-4, 2002.</Citation><Citation idx="9" PMID="12660384" MedlineID="22547205">Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (13): 1201-14, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_110"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/02/2015)</Title><Para id="_116">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.
</Para><Para id="_297">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062927#_AboutThis_1" url="http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of chronic myeloproliferative neoplasms. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Chronic Myeloproliferative Neoplasms Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem><ListItem>Mikkael A. Sekeres, MD, MS (Cleveland Clinic Taussig Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Chronic Myeloproliferative Neoplasms Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq">http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-04-02</DateLastModified></Summary>
